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Programmed degradation of mitochondria by mitophagy, an essential process to maintain
mitochondrial homeostasis, is not completely understood. Here we uncover a regulatory
process that controls mitophagy and involves the cAMP-degrading enzyme phosphodies-
terase 2A2 (PDE2A2). We find that PDE2A2 is part of a mitochondrial signalosome at the
mitochondrial inner membrane where it interacts with the mitochondrial contact site and
organizing system (MICOS). As part of this compartmentalised signalling system PDE2A2
regulates PKA-mediated phosphorylation of the MICOS component MIC60, resulting in
modulation of Parkin recruitment to the mitochondria and mitophagy. Inhibition of PDE2A2 is
sufficient to regulate mitophagy in the absence of other triggers, highlighting the physiolo-
gical relevance of PDE2A2 in this process. Pharmacological inhibition of PDE2 promotes a
‘fat-burning’ phenotype to retain thermogenic beige adipocytes, indicating that PDE2A2 may
serve as a novel target with potential for developing therapies for metabolic disorders.
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3′-5′-cyclic adenosine monophosphate(cAMP) is a ubiquitous and pleio-tropic second messenger. Among
its many functions, cAMP mediates the response to multiple
neurotransmitters in the nervous system, is the key controller of
rate and strength of cardiac contraction and is a master regulator
of cellular metabolism. Synthesis of cAMP is triggered by sti-
mulation of G protein-coupled receptors and activation of ade-
nylyl cyclase (AC) enzymes anchored at the plasma membrane1
or activation of an intracellular AC sensitive to bicarbonate2. A
rise in intracellular cAMP can translate, within the same cell, into
a multitude of different functional effects, from modulation of
metabolism to regulation of gene transcription, from control of
cell division to regulation of cell death. The complex and in some
case opposing effects of cAMP require precise coordination in
order for a specific extracellular stimulus to result in the appro-
priate cellular response, a process that relies on compartmenta-
lisation of the signaling events at distinct signalosomes3.
Typically, within a signalosome, an A Kinase anchoring protein
(AKAP) segregates the main cAMP effector, the protein kinase A
(PKA), in proximity to a specific phosphorylation target4. Selec-
tive activation of differently localized PKA subsets is achieved by
confining the increase in cAMP triggered by a specific stimulus to
the subcellular site, or nanodomain, within which the relevant
AKAP/PKA/target signalosome resides, enabling rapid and
selective PKA-dependent phosphorylation5–7. Phosphodiesterases
(PDEs), a superfamily of enzymes that degrade cyclic nucleotides
and comprise 11 families (PDE1-11) with multiple isoforms, play
a central role in confining cAMP within individual subcellular
nanodomains and in determining the amplitude and kinetics of
the local cAMP signal8. This is often achieved via anchoring
specific PDE isoforms to the signalosome via protein-protein
interactions9.
Mitochondria are indispensable organelles with central func-
tions in cellular energetics, metabolism and survival. Dysfunc-
tional mitochondria have been linked to pathological conditions
ranging from neurodegeneration and cardiomyopathies to cancer
and metabolic disorders10. Consistent with their multifunctional
role, mitochondria are under the control of a complex system of
signaling pathways and regulatory mechanisms. They form a
highly dynamic network where fusion and fission events and
quality control processes are fine-tuned to maintain cellular
energy homeostasis11,12. The cAMP/PKA signaling pathway has
emerged as a direct means to regulate mitochondria physiol-
ogy13–16 via PKA-dependent phosphorylation of several mito-
chondrial proteins involved in mitophagy and fusion/fission
dynamics17–19. An example of cAMP-dependent regulation of
mitochondrial dynamics is adipocyte plasticity. In adipocytes,
cAMP is pivotal in early stages of differentiation and in deter-
mining the transition between white adipocytes, that store energy
in the form of fat, and beige adipocytes, that dissipate energy by
burning lipids. Beige adipocytes mimic brown adipocytes with
multiple small lipid droplets and high content of mitochondria
that express the uncoupling protein 1 (UCP1)20. This process is
known as ‘browning’ or ‘beiging’ and is characterized by reduced
mitophagy and accumulation of mitochondria21–23.
In mitochondria, multiple AKAPs anchor PKA to different
organelle compartments. For example, AKAP1 docks PKA to the
mitochondrial outer membrane (MOM)24 whereas the AKAP
sphingosine kinase interacting protein (SKIP) tethers PKA to the
mitochondria intermembrane space (MIS)25. The presence of
several AKAPs at the mitochondria suggests that multiple and
functionally independent cAMP/PKA signaling domains may
operate at this organelle26. However, the specific functional role
of these distinct submitochondrial domains and their regulation
is not completely understood.
PDE2A, a dual-specificity PDE family, is expressed in a
number of tissues including brain, heart, liver, lung, adrenal
gland, and adipose tissue27. PDE2A contains a tandem pair of
regulatory domains (GAF-A and GAF-B). While the function of
GAF-A is unclear, binding of cGMP to the GAF-B domain
allosterically activates PDE2A catalytic activity28. Genetic abla-
tion of Pde2a results in embryonic lethality29, indicating its
involvement in fundamental biological functions. Three protein
variants of PDE2A are expressed (PDE2A1, PDE2A2, and
PDE2A3) that differ in their amino termini, which are respon-
sible for different subcellular localisation30. Of these isoforms,
PDE2A2 localizes to the mitochondria, PDE2A1 is pre-
dominantly cytosolic and PDE2A3 localizes largely to the plasma
membrane31. At the mitochondria, a subset of PDE2A2 was
reported to reside in the matrix and to control oxidative phos-
phorylation32. In previous studies, we found that PDE2A2
localizes to mitochondrial membranes, largely at the mitochon-
drial inner membrane (MIM), and regulates mitochondria
fusion/fission31. A fraction of PDE2A2 localizes outside the
mitochondria31.
In an attempt to define the molecular basis for the differential
subcellular localization of PDE2A2, here we studied the
PDE2A2 interactome using mass spectrometry (MS). Our
analysis reveals that PDE2A2 interacts with the mitochondrial
contact site and organizing system (MICOS) localized at the
MIM. We show that, in a variety of cell lines and primary cells,
PDE2A2 regulates a local pool of cAMP that controls PKA-
dependent phosphorylation of the MICOS component MIC60.
We further demonstrate that modulation of PDE2A2 activity at
MICOS regulates recruitment of Parkin to the organelle and
mitophagy and that PDE2A2 inhibition promotes adipocyte
browning.
Results
PDE2A2 interacts with MICOS. To determine the interactome
of PDE2A2, we used MS-based proteomics. For this purpose,
Strep-tagged PDE2A2 and, as a control, Strep-tagged elongation
factor thermo stable (EF-Ts) were overexpressed in the mouse
neuroblastoma cell line HT-4 and immunoprecipitated using an
anti-Strep-tag antibody. The pulldown proteins were analyzed by
MS and accurately quantified using the LFQ algorithm of the
MaxQuant computational platform33. A full list of interactors
that we found to be significantly enriched in the PDE2A2 pull
down is shown in Supplementary Data 1. Consistent with pre-
vious evidence31,32,34, the MS screen revealed a large number of
mitochondrial proteins (Fig. 1a). Gene Ontology Cellular Com-
partment (GOCC) term analysis (Supplementary Data 2) showed
a significant enrichment selectively for proteins localized at
mitochondrial membranes (term “Mitochondrial membrane”, p-
value 3.13E-05 and FDR 2.61E-3). Among those, we identified
two core components of MICOS, namely MIC60 (IMMT) and
MIC19 (ChChD3), as well as SAMM50 and Metaxin-2 (MTX-2),
a core subunit and an associate component, respectively, of the
Sorting and Assembly machinery (SAM), a protein complex
known to interact with MICOS35–38 (Fig. 1a).
Consistent with an interaction of PDE2A2 with MICOS,
immunolabelling of the neuronal cell line ShSy5y expressing
PDE2A2-GFP with an antibody specific for MIC60 shows signal
overlap at the mitochondria (Fig. 1b). Interaction of PDE2A2
with MICOS was confirmed by co-immunoprecipitation from
HEK293T cells expressing PDE2A2-RFP and MIC60-FLAG,
SAMM50-FLAG or Metaxin2-FLAG (Supplementary Fig. 1a–d).
Interaction of PDE2A2 with MICOS was also confirmed by co-
immunoprecipitation of endogenous MIC60 (Fig. 1c), MIC19
(Fig. 1d) or SAMM50 (Fig. 1e) from HEK293T cells expressing
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PDE2A2-RFP. In addition, endogenous PDE2A was detected in the
immunoprecipitate from rat brain homogenates obtained by
pulldown of endogenous MIC60 (Fig. 1f). The interaction of
MICOS with PDE2A is isoform-specific as co-immunoprecipitation
experiments in HEK293T cell expressing PDE2A1-GFP, PDE2A2-
GFP or PDE2A3-GFP and MIC60-FLAG show selective interaction
of MIC60-FLAG with PDE2A2-GFP (Fig. 1g).
PDE2A2 interacts with MICOS through the GAF-B domain.
To further characterize the interaction between PDE2A2 and
MICOS we generated a set of PDE2A2-RFP deletion mutants, as
illustrated in Supplementary Fig. 2a, b. The N-terminus is con-
sidered to be the region upstream (1-201 aa) of the GAF-A and
GAF-B domains. Consistent with previous findings32, confocal
images of HeLa cells transiently expressing the PDE2A2-RFP
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fragments (Supplementary Fig. 2c) and Western blot analysis of
subcellular mitochondrial fractions generated from HEK293T
expressing the PDE2A2-RFP deletion mutants (Supplementary
Fig. 2d), confirmed that only fragments including the N-terminal
region localize to the mitochondria. Further dissection of the
PDE2A2 N-terminal domain (Supplementary Fig. 3b) revealed
that, although required, the unique PDE2A2 region spanning
amino acid 1-17 is not sufficient to target the protein to the
mitochondria and that additional residues between aa 17 and aa
201 are required for full targeting (Supplementary Fig. 3b, c).
To characterize the interaction between MICOS and PDE2A2,
co-immunoprecipitation experiments were conducted in
HEK293T cells expressing PDE2A2-RFP deletion mutants and
MIC60-FLAG. As shown in Fig. 2a, only fragments that contain
the GAF-B domain and are targeted to the mitochondria (i.e.
included the PDE2A2 N-terminal domain) co-
immunoprecipitated with MIC60. Consistently, two additional
deletion mutants, N-terminal+GAF-B-RFP and ΔGAF-B-RFP
(Supplementary Fig. 3d), both of which localise to the
mitochondria as expected (Supplementary Fig. 3e, f), co-
immunoprecipitate with MIC60, confirming that the GAF-B
domain of PDE2A2 contains the interaction site for MICOS
although, for this interaction to occur, the PDE2A2 N-terminus is
required to target the GAF-B domain to the mitochondria
(Fig. 2b). To further confirm that the GAF-B domain, when
targeted to the mitochondria, is sufficient for binding to MICOS,
we generated a modified version of N-terminal+GAF-B-RFP
where we substituted the PDE2A2 mitochondrial targeting
domain (1-41 aa) with the mitochondrial targeting sequence
from the protein Smac/DIABLO39 (1-59 aa) (Supplementary
Fig. 3d). We found that this chimera correctly localises to the
mitochondria (Supplementary Fig. 3e, f) and efficiently interact
with MIC60 (Fig. 2c). The fact that all PDE2A isoforms contain
the GAF-B domain (Supplementary Fig. 3a) but only PDE2A2
interacts with MICOS indicates that this interaction only occurs
at the mitochondria.
PDE2A2 regulates PKA-mediated phosphorylation of MIC60.
MIC60 is phosphorylated by PKA19. Consistently, we found that
HEK293T cells expressing MIC60-FLAG and treated with the AC
activator forskolin (1 μM) for 2 h show significantly increased
PKA-dependent phosphorylation of MIC60 compared to control
(Fig. 3a). Given the interaction of PDE2A2 with MICOS, we
hypothesized that PDE2A2 hydrolyzes a local pool of cAMP at
the mitochondria that regulates PKA-dependent phosphorylation
of MIC60. To test this hypothesis, we treated HEK293 cells with
the PDE2A selective inhibitor Bay 60‐7550 (BAY) for 2 h and
found significant enhancement of MIC60 phosphorylation com-
pared to control (Fig. 3a, longer exposure panel and 3b). The
increased level of MIC60 phosphorylation observed is PKA-
Fig. 1 PDE2A2 interacts with MICOS components. a Volcano plot of the PDE2A2 interactome. Filled circles indicate proteins significantly pulled-down with
PDE2A2. Highlighted in orange are proteins annotated to the GOCC category “Mitochondrial membrane” and in blue are proteins annotated to the category
‘Mitochondrial matrix’. PDE2A2, MICOS components and MICOS-interacting proteins are shown in red. b Confocal images of Sh-Sy5y cells expressing
PDE2A2-GFP. Cells were fixed and immunostained with GFP- (red), MIC60- (turquoise) specific antibodies. Images are representative of two independent
experiments. Scale bar: 10 μm. c Detection of endogenous MIC60 after PDE2A2-RFP or mRFP immunoprecipitation from lysates obtained from
HEK293T cells transiently expressing either PDE2A2-RFP or mRFP. d Detection of endogenous MIC19 after PDE2A2-RFP or mRFP immunoprecipitation from
lysates obtained from HEK293T cells transiently expressing either PDE2A2-RFP or mRFP. e Detection of endogenous SAMM50 after PDE2A2-GFP or GFP
immunoprecipitation from lysates obtained from HEK293T cells transiently expressing either PDE2A2-GFP or GFP. f Detection of endogenous PDE2A after
immunoprecipitation of endogenous MIC60 from rat brain cell lysates. g Detection of endogenous MIC60 after immunoprecipitation of each PDE2A isoform
from lysates obtained from HEK293T cells transiently expressing PDE2A1-GFP, PDE2A2-GFP, PDE2A3-GFP or PDE2A4-GFP. PDE2A4, a variant whose
sequence has been deposited (NCBI Reference Sequence: NM_001146209.2) but for which no further characterization is available, was used here as a
control. All blots are representative of three independent experiments except from data shown in (f), which is representative of two independent
experiments. WCL whole-cell lysate.
Fig. 2 The GAF-B domain of PDE2A2 is necessary for the interaction with MIC60. a Detection of MIC60-FLAG after PDE2A2-RFP fragments
immunoprecipitation from cell lysates obtained from HEK293T cells transiently expressing PDE2A2-RFP deletion constructs and MIC60-FLAG. Pull-down
of mRFP was used as a negative control. Blot is representative of three independent experiments. b Detection of MIC60-FLAG after immunoprecipitation of
PDE2A2-RFP fragments from cell lysates obtained from HEK293T cells transiently expressing PDE2A2-RFP constructs and MIC60-FLAG, as indicated.
Pull-down of mRFP was used as a negative control. Blot is representative of two independent experiments. c Detection of MIC60-FLAG after
immunoprecipitation of N-terminal+GAF-B-RFP or MIS-linker+GAF-B-RFP from cell lysates obtained from HEK293T cells transiently expressing the
constructs. Pull-down from untransfected cell lysate was used as a negative control. Blot is representative of three independent experiments.
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dependent, as it was blocked by treatment with the PKA inhibitor
H89 (Supplementary Fig. 4a, b). Combined application of BAY
and Forskolin showed an additive effect that was not significantly
different from treatment with forskolin in combination with the
global PDE inhibitor Isobutyl-methyl-xanthine (IBMX) (Fig. 3a,
c), suggesting that PDE2A is the predominant PDE responsible
for the modulation of PKA-mediated phosphorylation of MIC60.
Similar results were observed in the human neuroblastoma cell
line Sh-Sy5y (Fig. 3d, e). Increased PKA-dependent phosphor-
ylation of MIC60 was found also when cAMP synthesis in
HEK293 was induced via a physiological activation of β-
adrenergic receptors with low doses (10 nM) of Isoproterenol
(ISO) (Fig. 3f, g). We also examined the level of PKA-dependent
phosphorylation of MIC60 in mouse embryonic fibroblasts
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01311-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:596 | https://doi.org/10.1038/s42003-020-01311-7 | www.nature.com/commsbio 5
obtained from a line homozygous for the deletion of the PDE2A
gene (MEFPDE2A−/−)31 and found a higher baseline level of
MIC60 phosphorylation compared to wild type cells (MEFWT)
(Fig. 3h, i). Consistently, overexpression of PDE2A2 completely
abolished the increased phosphorylation of MIC60 resulting from
treatment with 1 μM forskolin (Supplementary Fig. 4c, d).
Overall, the above data demonstrate that PDE2A2 regulates PKA-
dependent phosphorylation of MIC60.
PDE2A2 promotes recruitment of Parkin and mitophagy.
PKA-dependent phosphorylation of MIC60 inhibits recruitment
of Parkin to the MOM19. We therefore investigated whether
MICOS-interacting PDE2A2 may regulate this process. When
cells expressing mCherry-Parkin were treated with the proto-
nophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP),
Parkin was recruited to mitochondria (Supplementary Fig. 5). In
line with previous findings19,40, the elevation of cAMP in MEFWT
treated with Forskolin significantly reduced, in a concentration-
dependent manner, mitochondrial recruitment of Parkin
(Fig. 4a). To assess a possible regulatory role of PDE2A2 on
mitochondrial Parkin recruitment we expressed in MEFWT either
PDE2A2-GFP or, as a control, PDE2A1-GFP. Unlike PDE2A2-
GFP, which shows a clear mitochondrial localization, PDE2A1-
GFP distributes homogeneously in the cytosol (Supplementary
Fig. 6). As shown in Fig. 4a, expression of PDE2A2-GFP, but not
of PDE2A1-GFP or of the mitochondria-targeted mito-mEmerald
(Supplementary Fig. 6) significantly increased Parkin recruitment
to depolarized mitochondria, both in untreated cells and in cells
treated with Forskolin. At higher concentrations of Forskolin the
amount of cAMP generated appears to overcome the hydrolytic
activity of PDE2A2. In HEK293T cells the effect of CCCP on
Parkin recruitment was also blocked by elevation of cAMP
induced by β-adrenergic receptor stimulation with ISO (Fig. 4b).
In these cells expression of PDE2A2-GFP counteracted the
inhibitory effect of ISO, an effect that was not observed in cells
expressing PDE2A1-GFP or mito-mEmerald (Fig. 4c, d). Notably,
expression of PDE2A2-GFP, but not expression of PDE2A1-GFP
or GFP alone, was sufficient to increase by two-fold the mito-
chondrial recruitment of Parkin in MEFwt even in the absence of
CCCP (Fig. 4e and Supplementary Fig. 7). The effect of PDE2A2
on Parkin recruitment relies on the enhanced local hydrolysis of
cAMP at the mitochondria as Parkin recruitment was not
enhanced by expression of a catalytically inactive point mutant of
PDE2A2 (PDE2A2_DN-RFP) or N-term+GAF-B-RFP (Fig. 4f
and Supplementary Fig. 8) a truncated mutant of PDE2A2 that
localizes to mitochondria (Supplementary Fig. 3d–f) and interacts
with MICOS (Fig. 2b) but lacks the catalytic domain.
Recruitment of Parkin to mitochondria is one of the best-
characterized mechanisms leading to mitophagy. To more
directly assess whether PDE2A2 activity at MICOS modulates
mitophagy, we measured co-localization of mitochondria and
LC3 (Microtubule-associated proteins 1A/1B light chain 3B), a
protein involved in autophagy and commonly used as a marker of
autophagosomes41. For this purpose we co-transfected MEFWT
with LC3-GFP, mRFP as a marker for mitochondria, and
PDE2A2, and found significantly enhanced LC3/mRFP co-
localization, and thus mitophagy, when compared with expres-
sion of PDE2A1, confirming the selective involvement of isoform
2 of PDE2A (Fig. 4g). Notably, PDE2A2 expression did not affect
the total number of LC3 puncta (Fig. 4h), which is a measure of
global autophagy42, confirming a role of PDE2A2 selectively in
the regulation of mitophagy.
In further support of its role in the regulation of mitophagy, we
found that overexpression of PDE2A2 significantly increased the
number of cells showing mitophagy puncta as detected by the
mito-QC reporter43 (Fig. 4i, j). This effect was not recapitulated
by overexpression of either PDE2A1 or PE2A3, indicating a
specific role of the 2A2 isoform (Fig. 4i, j).
PDE2A inhibition blocks Parkin recruitment and mitophagy.
We next assessed whether pharmacological inhibition of endo-
genous PDE2A activity results in reduced Parkin recruitment and
inhibition of mitophagy. As shown in Fig. 5a, b, treatment with
BAY prevented Parkin translocation to the mitochondria induced
by CCCP, even in the absence of cAMP raising agents. The
combination of 1 μM BAY and 1 nM ISO showed additive effect,
resulting in more prominent reduction in Parkin recruitment
compared to the individual treatments (Fig. 5a, b). The effect of
both ISO and BAY relies on PKA-mediated phosphorylation as it
was completely abolished in cells expressing the selective PKA
inhibitor peptide PKI44 (Fig. 5c). The ability of PDE2A inhibition
to reduce mitophagy was confirmed in experiments where
MEFWT expressing mito-QC were treated with CCCP alone or in
combination with BAY or, as a control, the PDE3 inhibitor
cilostamide (Fig. 5d, e), a selective PDE3 inhibitor that generates
cAMP at the mitochondria, albeit at a significantly lower level
(Fig. 5f).
The effects of pharmacological inhibition were recapitulated by
genetic ablation of PDE2A. We compared MEFWT and
MEFPDE2A−/− and found that PDE2A KO results in significantly
attenuated Parkin recruitment both in the absence and in the
presence of CCCP (Fig. 5g and Supplementary Fig. 9). While 100
nM ISO significantly reduced Parkin recruitment in CCCP-
treated MEFWT, as observed in HEK cells (Fig. 4b), no effect of
ISO was observed in MEFPDE2A−/− (Fig. 5h, j), indicating that
the effect of adrenergic stimulation is entirely recapitulated by
PDE2A ablation. Consistently, inhibition of PDE2A with BAY
reduced Parkin recruitment in CCCP-treated MEFWT but showed
no effect in MEFPDE2A−/− (Fig. 5i, j).
To confirm a role for PKA-dependent phosphorylation of MIC60
in the reduced recruitment of Parkin observed in MEFPDE2A−/−,
we used MIC60 phospho-deficient (S528A) and phospho-mimetic
(S528D and S528E) mutants at the PKA phosphorylation site19.
Expression of MIC60WT and MIC60S528A significantly increased
Fig. 3 PDE2A controls the phosphorylation status of MIC60. a Representative western blot and (b, c) quantification of the phosphorylation status of
MIC60 in HEK293T cells expressing MIC60-FLAG and treated with Forskolin for 2 h. N= 4. d Representative western blot and e quantification of MIC60
phosphorylation status in ShSy5y cells overexpressing MIC60-FLAG and treated with Forskolin for 2 h. N= 3. f Representative western blot and
g quantification of MIC60 phosphorylation level detected in HEK293T cells expressing MIC60-FLAG and treated with ISO (10 nM) alone or in combination
with H89 for 2 h. N= 3. h Representative western blot and i quantification of MIC60 phosphorylation in WT or PDE2A−/− MEF cells expressing MIC60-
FLAG and either treated or non-treated with Forskolin and IBMX for 1 h. N= 5. For all panels, a phospho-(Ser/Thr) PKA substrate antibody (RRx(S/T)P)
was used both on whole-cell lysate (WCL) and on MIC60-FLAG pulled-down samples (IP). The amount of phosphorylated MIC60 was normalized to the
amount of precipitated MIC60 and is shown as the fold change relative to levels in DMSO-treated cells, except for (c) and (i), where values are shown as
the fold change relative to levels in Forskolin-treated cells and as the fold change relative to levels detected in WT cells treated with Forskolin/IBMX (FI),
respectively. All values represent mean ± s.e.m. One-way ANOVA and Tukey’s multiple comparison tests. Student’s t-test comparisons are shown in gray
*P < 0.05; **P < 0.01; ***P < 0.005; ns= not significant.
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mCherry-Parkin recruitment in both MEFWT and MEFPDE2A−/−
(Fig. 5k). In contrast, expression of MIC60S528D and MIC60S528E
reduced the intracellular localization of mCherry-Parkin, consistent
with the observation that PKA-mediated phosphorylation of MIC60
attenuates Parkin recruitment to the mitochondria19. In all cases,
the difference in mCherry-Parkin recruitment between MEFWT and
MEFPDE2A−/− was abrogated (Fig. 5k), confirming that PDE2A2
regulates Parkin recruitment via phosphorylation of MIC60 at the
PKA site.
We also found that MEFsPDE2A−/−, which have increased
MIC60 phosphorylation (Fig. 3h, i), presented mitochondria with
intact cristae morphology (Fig. 5l) supporting previous findings
that PKA-dependent regulation of MICOS affects Parkin
recruitment independently from mitochondrial membrane
structure19.
Inhibition of PDE2A modulates basal mitochondria clearance.
Treatment with CCCP results in severe mitochondria depolar-
ization that is unlikely to reflect physiological conditions. To
assess whether inhibition of PDE2A may impact mitochondria
clearance in a physiological setting we treated MEFWT with BAY
in otherwise untreated cells. Consistent with the higher level of
PKA-dependent phosphorylation of MIC60 that we observed
upon inhibition of PDE2 in untreated HEK293 cells (Fig. 3a, b
and Supplementary Fig. 4) and Sh-SY5Y cells (Fig. 3d), inhibition
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of PDE2A was effective in reducing Parkin recruitment to
mitochondria in MEFWT not treated with CCCP; by contrast,
treatment with cilostamide did not show the same effect (Fig. 6a
and Supplementary Fig. 10). Reduced overlap of LC3 puncta and
mRFP (Fig. 6b) and unchanged overall number of LC3 puncta
(Fig. 6c) confirmed that ablation of PDE2A activity specifically
attenuates mitophagy in these cells. Notably, inhibition of
PDE2A, but not of PDE3, also resulted in significant reduction of
Parkin recruitment in inducible human pluripotent stem cell-
derived dopaminergic neurons (Fig. 6d and Supplementary
Fig. 11). The effect of PDE2A inhibition on basal mitophagy was
further confirmed by the observation that MEFWT expressing
mito-QC and treated with BAY, but not with cilostamide, show
reduced number of mitophagy puncta compared to control cells
(Fig. 6e, f).
PDE2A inhibition controls PINK1 stability on mitochondria.
Parking localization to mitochondria is directly regulated by
phosphatase and tensin homolog-induced kinase 1 PINK145 and
CCCP treatment is known to stimulate autophosphorylation of
PINK1 and its stabilization on depolarized mitochondria46
(Fig. 7a, b). On the other hand, PKA-dependent phosphorylation
of MIC60 destabilises MIC60-PINK1 interaction and results in a
decline in the amount of PINK1 due to its rapid degradation by
the proteasome19, an effect that is recapitulated by treating
HEK293T cells with 25 μM forskolin for 60 min (Fig. 7a, b). We
therefore asked whether PDE2A inhibition regulates
PINK1 stability on mitochondria through this mechanism. As
shown in Fig. 7a, b, inhibition of PDE2A with BAY resulted in a
small reduction in the amount of PINK1. The effect of PDE2A
inhibition was however significantly amplified (60% reduction in
total PINK1) when cells were simultaneously treated with 100 nM
ISO and 1 μM BAY. In further support of the role of PDE2A2, we
found that the effect of PDE2A inhibition on PINK1 stability was
completely recapitulated by overexpression of the catalytically
inactive mutant PDE2A2DN (Fig. 7c, f). PDE2A2DN contains 2
D to A point mutations at positions 685 and 796 in the enzyme
catalytic site that completely abolish the ability to hydrolyse
cAMP while maintaining the enzyme ability to participate in
protein-protein interactions and anchor to subcellular sites44,47.
Overexpression of this mutant is expected to displace endogenous
active PDE2A2 at the mitochondria.
PDE2A regulates adipocyte browning. To assess the relevance of
PDE2A2-dependent regulation of mitophagy in a physiologically
relevant context, we focused on white adipocytes. Activation of
cAMP signaling in these cells, e.g., via norepinephrine (NE) sti-
mulation, is known to lead to the transition from a fat storing
(white) to an energy expending, mitochondria-rich (beige) phe-
notype, a process that involves attenuated mitophagy. We found
that, as observed in HEK293 cells (Fig. 7a, b), CCCP treatment
stabilizes PINK1 in white adipocytes (Fig. 8a, b) and inhibition of
PDE2A potentiates the effect of ISO in promoting reduction of
PINK1 levels (Fig. 8a, b). In addition, we found that BAY sig-
nificantly enhanced the expression of nuclear thermogenic genes
and mitochondrial markers in white adipocytes treated with NE,
as shown both at the mRNA (Fig. 8c) and protein level (Fig. 8d,
e). To further gauge the size of the mitochondrial pool, we also
assessed expression of mitochondrially encoded genes relative to a
nuclear housekeeping gene (Hprt)48. We found that inhibition of
PDE2A enhances the effect of NE on overall mitochondrial gene
expression, suggesting that PDE2A regulates mitochondrial con-
tent in adipocytes (Fig. 8f). Consistent with a role of PDE2A in
the control of mitochondrial content via regulation of mitophagy,
we found that inhibition of PDE2A significantly enhanced UCP1-
dependent oxygen consumption in adipocyte treated with NE
(Fig. 8g). In addition, we observed that inhibition of PDE2A in
white adipocytes treated with NE further enhanced the decrease
in lipid droplet size (Fig. 8h). All together, these data indicate that
inhibition of PDE2A enhances cAMP induced ‘beiging’21–23 via
promoting reduction of PINK1 levels.
Discussion
In this study we discovered that PDE2A2 interacts with MICOS
at mitochondrial membranes; we established that, for this inter-
action to occur, PDE2A2 must be targeted to the mitochondria
via its N-terminal domain (amino acids 1-201) and that the
interaction itself involves the PDE2A2 regulatory GAF-B domain.
We demonstrate that mitochondrial PDE2A2 controls a local
pool of cAMP that regulates PKA-mediated phosphorylation of
the MICOS component MIC60. We further demonstrate that the
MICOS/PDE2A2/cAMP/PKA signalosome modulates Parkin
recruitment to the mitochondria and mitophagy.
At least 100 different PDE isoforms are predicted to be
expressed in cells49. The diversity of kinetics properties, substrate
binding affinities, subcellular localization and regulatory
mechanisms of individual PDE isoforms make this enzyme sys-
tem ideally suited to fine-tune cAMP signals at a subcellular local
level. PDEs are attractive therapeutic targets for precision medi-
cine8 as manipulation of the activity of individual PDE isoforms
results in local cyclic nucleotide changes that are expected to
impact specific cellular functions and limit side effects8. Dis-
secting the subcellular localization of individual PDE isoforms
Fig. 4 Effect of increased PDE2A2 activity on the recruitment of Parkin to the mitochondria and mitophagy. a Number of MEFWT with mitochondrial
Parkin. Cells expressing mCherry-Parkin and either mito-mEmerald, PDE2A1-GFP or PDE2A2-GFP were treated with Forskolin for 60min followed by 180
min incubation with 10 µM CCCP. n≥ 52, N= 3-4. b HEK293T cells expressing mCherry-Parkin upon 120min incubation with 10 µM CCCP or 60min with
10 nM Isoproterenol (ISO) followed by 120min incubation with 10 µM CCCP. c Representative images and summary data (d) showing number of
HEK293T cells with mitochondrial Parkin. Cells expressing mCherry-Parkin and either mito-mEmerald, PDE2A1-GFP or PDE2A2-GFP were treated with 10
nM Isoproterenol (ISO) for 60min followed by 120min incubation with 10 µM CCCP. n≥ 112 cells, N= 9. e Number of MEFWT with mitochondrial Parkin,
24 h after co-transfection with mCherry-Parkin and either GFP, PDE2A1-GFP or PDE2A2-GFP. n≥ 48 cells, N= 5. f Number of MEFWT with mitochondrial
Parkin, 24 h after co-transfection with GFP-Parkin and either mRFP, N-term-GAF-B-RFP, PDE2A2-RFP or PDE2A2_DN-RFP. n≥ 89 cells, N= 4. g
Quantification of colocalisation of the signal generated by GFP-LC3 puncta and mRFP determined in MEFWT cells expressing either PDE2A1-FLAG or
PDE2A2-FLAG. The broken line indicates level of colocalisation in cells not tranfected with PDE2A isoforms. n≥ 15 cells, N= 3. h Number of GFP-LC3
positive puncta in HeLa cells co-transfected with GFP-LC3 and either mRFP, PDE2A1-RFP or PDE2A2-RFP. n≥ 79 cells, N= 3. i Representative imeges and j
summary data showing number of mitophagy puncta in MEFwt expressing mito-QC and transfected with PDE2A1-FLAG, PDE2A2-FLAG or PDE2A3-FLAG.
The expression of PDE isoform was identified by immunostaining using an anti-FLAG antibody. As a control, puncta in cells from the same coverslip but
negative for FLAG antibody signal are shown. Data are from n≥ 46 cells, N= 3. Scale-bars represent 20 µm for (b) and (c), 25 µm for (i). All values
represent mean ± s.e.m. One-way ANOVA and Tukey’s multiple comparison tests were performed for (a, d, e, f and h). Two-way ANOVA and Holm-
Sidak’s multiple comparison tests were performed for (j). Student’s t test was performed for (g). *P < 0.05; **P < 0.01; ***P < 0.005; ns= not significant.
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and defining their functional role at distinct sites is therefore
important. One approach to this undertaking is to analyze the
interactome of individual PDE isoforms.
We previously demonstrated that isoform 2 of PDE2A pre-
dominantly, but not exclusively, localizes to mitochondrial
membranes where it controls Drp1 phosphorylation, mitochon-
dria elongation and apoptosis31. Other studies have reported
localization of PDE2A2 to the mitochondrial matrix and a role in
the regulation of oxidative phosphorylation50,51. However, the
molecular basis for the specific sub-mitochondrial localization of
PDE2A2 had not been explored. Our GO category enrichment
analysis of the PDE2A2 interactome shows a significant enrich-
ment of both plasma membrane and intracellular membranes
categories (Supplementary Data 2), supporting the localization of
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PDE2A2 at multiple subcellular sites. In the category enrichment
analysis of our PDE2A2 pull-down, we found the category
‘mitochondrial membranes’ significantly enriched (Supplemen-
tary Data 2), while only one protein annotated to the GO category
‘mitochondrial matrix’ (BCL2L1, a protein involved in apoptosis
and mostly abundant at the MOM52), which suggested that
PDE2A2 more likely localizes at mitochondrial membranes.
Within the ‘mitochondrial membranes’-annotated proteins, the
MICOS components MIC60 and MIC19 were particularly inter-
esting potential interactors of PDE2A2. MICOS is an evolutio-
narily conserved multiprotein system localized at the MIM and
essential for cristae junction formation and maintenance53. In
addition, MICOS establishes contact sites between the MIM and
the MOM that facilitate mitochondrial protein import and are
involved in phospholipid metabolism and distribution within
mitochondria54. Interestingly, our interactome analysis shows
significant interaction of PDE2A2 also with the SAM complex,
which is involved in mitochondrial protein import, as well as with
proteins involved in the regulation of membrane lipid exchange
and phospholipid transport (Supplementary Data 1 and Supple-
mentary Data 2). Whether manipulation of PDE2A2 activity may
impact on these functions of MICOS warrants further studies.
MIC60 is an integral MIM protein and a central component of
MICOS53. Evidence supports its role as a scaffold that coordinates
multiple mitochondrial functions at cristae junctions52 and
undergoes phosphorylation-dependent regulation. PINK1-
mediated phosphorylation of MIC60 is required to maintain
cristae architecture55 whereas its phosphorylation by PKA inhi-
bits recruitment of Parkin to damaged mitochondria19. Here, we
demonstrate that genetic KO or pharmacological inhibition of
Fig. 5 Effect of PDE2A2 inhibition on Parkin recruitment and mitophagy. a Mitochondrial Parkin in HEK293T expressing mCherry-Parkin, treated with
ISO or BAY-60 for 1 h followed by 2 h treatment with 10 μM CCCP. n≥ 62 cells, N= 3. b Representative images for (A). Scale bar: 100 µm. c Mitochondrial
Parkin in HEK293T expressing GFP-Parkin and either mCherry or PKI-mCherry, upon 1 h treatment with ISO, BAY-60 or their combination followed by 10
μM CCCP treatment for 2 h. n≥ 211 cells, N= 4. d Representative images and (e) summary data showing MEFWT expressing mito-QC treated with CCCP
in the absence (DMSO) or presence of BAY-60 or cilostamide. (n≥ 112 cells, N= 3. Scale bar: 20 µm. f cAMP changes in MEFWT expressing the
mitochondrially targeted FRET reporter OMM-H9031 treated with either 1 μM BAY-60 or 10 μM Cilostamide. FRET change is expressed as relative to
maximal FRET change at saturation (25 μM Forskolin+ 100 μM IBMX). gMitochondrial Parkin in MEFWT or MEFPDE2−/− (KO) expressing mCherry-Parkin
untreated (NT) or treated with 10 μM CCCP for 3 h. n≥ 46 cells, N= 5. h Mitochondrial Parkin in MEFWT or MEFPDE2−/− expressing mCherry-Parkin.
Treatment: 10 μM CCCP for 3 h with or with 100 nM ISO for 1 h followed by 3 h treatment with 10 μM CCCP. n≥ 107 cells, N= 3. i Mitochondrial Parkin in
MEFWT or MEFPDE2−/− expressing mCherry-Parkin and treated with 10 μM CCCP for 3 h or 1 μM BAY-60 for 1 h followed by 2 h treatment with 10 μM
CCCP. n≥ 165 cells, N= 3. j Representative cells for (g–h). Scale bar: 20 µm. k Mitochondrial Parkin in MEFWT or MEFPDE2−/− expressing mCherry-Parkin
and co-expressing either GFP, MIC60 wt, or the MIC60 mutants S528A, S528D or S528E. n≥ 50 cells, N= 4. Values are expressed as mean ± s.e.m. One-
way ANOVA and Tukey’s multiple comparison tests were performed for (a) and (e). Two-way ANOVA and Tukey’s multiple comparison tests were
performed for (c, g, h and i). Two-way ANOVA with Holm-Sidak’s multiple comparison test for k. Student’s t-test for f **P < 0.01; ***P < 0.005; ns = not
significant. (l) Transmission electron micrographs of MEFWT (PDE2+/+) and MEFPDE2−/− (PDE2−/−) cells. Scale bar: 2 μm.
Fig. 6 Effect of PDE2A2 inhibition on mitochondria clearance. a Quantification of mitochondrial Parkin in MEFWT expressing mCherry-Parkin and treated
with 1 μM BAY-60 or 10 μM Cilostamide (CILO) for 2 h. Dotted line indicates mitochondrial Parkin in untreated control. n≥ 33 cells, N= 4. b Overlap of
GFP-LC3 puncta with mitochondria in MEFWT or MEFPDE2−/− expressing GFP-LC3 and mRFP under basal conditions or treated with 1 μM BAY-60 or
10 μM Cilostamide for 2 h. n≥ 15 cells, N= 3. c Number of GFP-LC3 puncta in MEFWT and MEFPDE2A−/− transfected with GFP-LC3 under basal conditions.
n≥ 71, N= 5. d Quantification of mitochondrial Parkin localization in human iPSC-derived dopaminergic neurons expressing mCherry-Parkin under basal
conditions or after treatment with 1 μM BAY-60 or 10 μMCilostamide for 2 h. n≥ 67cells, N= 4. e Representative images and f quantification of mitophagy
puncta in MEFWT cells expressing mito-QC and treated with 1 μM BAY or 1 μM cilostamide. N≥ 157cells, N= 3. Scale bar in (e) represents 20 µm. All
values are expressed as mean ± s.e.m. One-way ANOVA and Tukey’s multiple comparison tests were performed for (b, d and f). Student’s t-test statistical
analysis was performed for (a and c). *P < 0.05; **P < 0.01; ***P < 0.005; ns= not significant.
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PDE2A drives increased PKA-dependent phosphorylation of
MIC60, reduces Parkin recruitment to the mitochondria and
attenuates mitophagy, while increased activity of PDE2A2, but
not of PDE2A1 or PDE2A3, shows the opposite result. This effect
likely involves destabilization of MIC60 interaction with PINK1
at the MOM as a consequence of PKA phosphorylation of
MIC60, and the consequent reduction of PINK1 levels by the
lysosomes19 as we find that suppressing the activity of PDE2A2 at
the mitochondria results in reduction of PINK1 protein levels. In
line with previous evidence that increased PKA phosphorylation
of MIC60 does not impact on cristae remodeling19, we show that
genetic ablation of PDE2A2 decreases mitophagy without
affecting mitochondrial structural integrity.
Inhibition of Parkin recruitment and mitophagy by the mito-
chondrial PDE2A2 but not the cytosolic isoform PDE2A1 or the
plasma membrane-targeted PDE2A3 strongly indicates that
PDE2A2 affects mitophagy via local modulation of cAMP at
MICOS. Our data also demonstrate that the effect of ISO sti-
mulation on Parkin recruitment is completely recapitulated by
genetic ablation of PDE2A. This finding suggests that adrenergic
stimulation controls mitophagy via the local change of cAMP
levels at the mitochondria and reveals a central physiological role
of PDE2A2 in the modulation of mitochondria clearance.
The regulation and roles of Parkin-dependent mitophagy are
not completely understood. Several studies show that a reduction
in the mitochondrial membrane potential leads to mitophagy
through stabilization of PINK1 at the MOM and subsequent
recruitment of Parkin41,45,56. In most in vitro studies, however,
highly toxic mitochondria uncouplers have been used to induce
Parkin recruitment and the nature of the triggers acting upstream
of PINK1-Parkin recruitment in physiological conditions has
been elusive. As a consequence, the relevance of this pathway in
the regulation of mitophagy in vivo remains controversial57 and
recent evidence suggests that Parkin-dependent mitophagy may
be context- and cell type-specific58. Equally uncertain are the
exact function and the signaling triggers driving basal mitophagy,
a process that occurs extensively across many tissues in the
absence of any overt stress59,60. Here we show that, in a number
of cell types, inhibition of PDE2A increases phosphorylation of
MIC60, reduces Parkin recruitment and attenuates mitophagy
even in the absence of any cAMP raising stimulus indicating that
PDE2A2-dependent hydrolysis of cAMP at the MICOS complex
regulates basal mitophagy. It is interesting to note that SKIP, an
AKAP that selectively binds PKA type I holoenzymes25, interacts
with MIC1961. Although in our study we did not directly address
the involvement of SKIP-anchored PKA in the phosphorylation
of MIC60, it is tempting to speculate that PDE2A2 is part of a
MICOS/SKIP/PKA-I signalosome at the MIM. This possibility is
particularly intriguing as SKIP can simultaneously bind two
molecules of the PKA type-I holoenzyme25, which is more sen-
sitive to cAMP than the PKA type-II isoform. A signalosome
organized by SKIP and MICOS at the MIM could therefore
experience significant PKA activity even at relatively low cAMP
concentrations, as one may expect in basal conditions. PDE2A2
catalytic activity is potently activated by cGMP. As cGMP levels
vary in response to ATP changes62 as well as physiological and
pathological stressors63, PDE2A2 provides a means to regulate
mitochondria clearance in response to metabolic fluctuations and
stress stimuli.
The cAMP-PKA pathway plays an outstanding role in adipo-
cytes. Apart from lipolysis—the release of free fatty acids from
adipocytes—cAMP signaling controls the metabolic phenotype
and mitochondrial content of these cells21,64. Upon activation of
cAMP signaling (e.g., via noradrenergic stimulation), white adi-
pocytes change their phenotype from a fat storing to an energy
expending cell, in a process known as “browning”, and become
so-called beige fat cells22,23. Beige adipocytes are characterized by
expression of thermogenic genes (including UCP1), increased
number of mitochondria, and attenuated Parkin recruitment and
mitophagy. Altogether, these mechanisms regulate energy
homeostasis and protect from diet-induced obesity41,65. Here we
show that PDE2A plays an important role in this process.
Interestingly, in vivo, β3-adrenergic stimulation leads to impaired
recruitment of Parkin, reduced mitophagy and retention of
mitochondria-rich beige adipocytes and thermogenesis via cAMP
and PKA activation40. This suggests that catecholamine-induced
changes in cAMP levels can trigger Parkin recruitment to mito-
chondria in the absence of a mitotoxic stress. Our results show
that, in several cell types, PDE2A2 can modulate Parkin
recruitment to mitochondria in the absence of CCCP indicating
that a local change of cAMP levels at MICOS and a change in the
level of MIC60 phosphorylation may be sufficient to modulate
Parkin translocation. We further show that inhibition of PDE2A
enhances browning of white adipocytes induced in vitro by
noradrenaline via destabilization of PINK1, supporting the notion
that a local increase in cAMP in the absence of mitotoxic stress
can reduce Parkin recruitment and limit mitophagy in these cells.
Further studies will be required to confirm the involvement of
MIC60 phosphorylation in adipocyte browning. However, our
findings are of general relevance for adipose tissue, since several
studies have documented mitochondrial loss in white adipose
tissue of obese and diabetic mice66,67. Understanding regulation
of autophagy and mitochondrial content in white and beige
adipocytes has value for developing novel therapies for metabolic
Fig. 7 PINK1 stability is regulated by PDE2A2 activity. a Representative western blot and (b) summary quantification of PINK1 levels in HEK293 whole-
cell lysates treated with forskolin 25 μM, BAY-60 1 μM or ISO 100 nM, as indicated, followed by CCCP 10 μM treatment for 2 h, as indicated. N= 3.
c Representative western blot and (d) summary quantification of PINK1 levels in HEK293 cells treated with CCCP 10 μM and forskolin 25 μM, as indicated,
in the absence or presence of PDE2A2-DN-RFP. N= 4. All values represent mean ± s.e.m. and are expressed as relative to the level of PINK1 detected in
cell treated with CCCP only. One-way (d) and two-way (b) ANOVA and Tukey’s multiple comparison test were used *P < 0.05; **P < 0.01; ***P < 0.005.
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disorders. Our results suggest that PDE2A inhibition can promote
a ‘fat-burning’ phenotype and may be an effective approach to
retain thermogenic beige adipocytes to control obesity.
Methods
Reagents and antibodies. Bay 60-7550 was from Cambridge Bioscience. Staur-
osporin was from Calbiochem. FuGeneHD was from Promega. Phosphate‐Buffered
Saline (PBS), Penicillin/Streptomycin, Trypsin 0.05%, Glutamine and
Lipofectamine 2000 were from Invitrogen. Unless otherwise noted, all other
reagents were obtained from Sigma-Aldrich. Antibodies against the following
proteins were used as recommended by the manufacturers: FLAG (Cell Signaling,
8146, 1:1000; Cell Signaling, 8146, 1:1000), GAPDH (SCBT, sc166574, 1:1000;
Proteintech, 60004-1-Ig, 1:1000), GFP (SCBT, sc9996, 1:1000; Abcam, ab6556,
1:1000), MIC60 (Abcam, ab110329, 1:500), Parkin (Cell Signaling, 4211, 1:500),
PDE2A (Proteintech, 55306-1-AP, 1:1000), phospho-(Ser/Thr) PKA substrate (Cell
Signaling, 2964, 1:1000), PINK1 (Cell Signaling, 6946, 1:500), RFP (Chromotek,
6G6, 1:1000; Abcam, ab62341, 1:1000), SAMM50 (Atlas Antibodies, HPA042935,
1:1000) and α-Tubulin (Abcam, ab18251, 1:5000); horseradish-peroxidase-
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conjugated goat anti-mouse or anti-rabbit secondary antibodies were also used
(SCBT, sc2005, 1:5000; SCBT, sc2030, 1:3000), as well as antibodies conjugated
with Alexa Fluor 647 (Thermo Fisher Scientific, A-21235, 1:250) and Alexa Fluor
532 (Thermo Fisher Scientific, A-11009, 1:250). Human pluripotent stem cell-
derived dopaminergic neurons were from Cellular Dynamics (R1032).
MS of the PDE2A2 interactome. Constructs encoding for PDE2A2 or, as a
control, EF-Ts (E.coli translation elongation factor Ts) tagged with a Strep-tag II
epitope at the carboxyl terminal were generated via recombination cloning using
the StarGatesytem (IBA BioTAGnology GmbH) following the manufacturer’s
instructions. For analysis of the PDE2A2 interactome HT-4 mouse neuroblastoma
cells were transfected with either pESG‐IBA103/PDE2 or pESG-IBA103/EF-Ts as a
control (EF-Ts= E. coli translation elongation factor Ts). Lysates from transfected
cells were used for immunoprecipitation with anti-StrepMab-Immo monoclonal
antibody covalently coupled to Dynabeads ® Protein G. Elution fractions were
separated on a 4–12% Bis-Tris Polyacrylamide gel for subsequent colloidal Coo-
massie staining, trypsinized and analyzed by MS (Linear Trap Quadrupole(LTQ)-
Orbitrap Velos, Thermo Fisher Scientific) as previously described68. The MS data
from two biological replicates were analyzed with the MaxQuant computational
platform69 (version 1.2.0.11). A false discovery rate of 1% was used for peptide and
protein identification. The label-free quantification (LFQ) algorithm33 was used for
protein quantification; only unique peptides were taken into account for protein
quantification. Re-quantify and Match between run were enabled for the analysis.
MS data were further analyzed with the Perseus module of MaxQuant70. First, only
identified by site, reverse and contaminant hits were removed from the interactome
and only proteins pulled-down with PDE2A2 in both replicate experiments were
considered for the analysis. Missing values in the control pull-down were replaced
using the Imputation tool with default parameters. A two sample t-test was used to
determine the interactome of PDE2A2, using a 10% FDR and S0 value of 0.2. For
category enrichment analysis of the PDE2A2 interactome, a Fisher exact test with
1% FDR was used.
Cell culture. All experiments using primary cells comply with ethical regulations
under the Animals (Scientific Procedures) Act 1986, section 5, and have been
approved by the Home Office, UK.
HeLa, HEK293T and MEF cells were grown in DMEM+ 10% FBS. Sh-Sy5y
were grown in DMEM/F12+ 10% FBS. All cell lines were maintained in a
humidified CO2 (5%) incubator at 37 °C and were split every 2-3 days after
reaching 80% confluence. Cells were tested each month for mycoplasma
contamination by PCR. All plasmids were transfected into HeLa cells using
FuGENE HD, into HEK293T cells using PEI or Lipofectamine 2000 and into MEFs
or Sh-sy5y cells using jetPRIME, according to manufacturer’s instructions.
MEFs isolation. Pregnant females obtained from crossing of heterozygous
PDE2KO mice (line B6;129P2-Pde2atm1Dgen/H, provided by EMMA, UK), were
sacrificed after 13 days of gestation (E.13 dpc) and the embryos collected, then
placed into separate dishes containing phosphate buffered saline (PBS). A segment
of the tail was removed for genotyping, whereas the head and the internal organs
were removed. The remaining tissue was washed with PBS and incubated in trypsin
at 37 °C for 5–10 min. The solution was pipetted until the tissue was completely
homogenized and the isolated cells were plated onto T75 flasks. For transfection
the cells were plated onto sterile 24 mm diameter coverslips and maintained at
37 °C for 24 h.
Isolation and culture of primary murine white adipocytes. Primary white adi-
pocytes were isolated from 8–12 weeks old C57BL/6 mice71. Inguinal WAT
(WATi) from three mice was dissected and digested in DMEM containing 0.5%
BSA and collagenase type II at 37 °C and then centrifuged at 1000 rpm for 10 min.
The resulting pellet was re-suspended and filtered using a 100 µm nylon mesh. The
filtered solution was seeded into a T175 culture flask in DMEM supplemented with
10% FBS and 1% P/S (WA Growth medium) and kept at 37 °C and 5% CO2. 24 h
after seeding, cells were washed with PBS and maintained in WA Growth medium
at 37 °C, 5% CO2. Medium was refreshed every day until cells reached confluency
and subsequently cryopreserved.
Cells were plated at a density of 140,000 cells per well in a 6-well plate in growth
medium. Cells were grown to confluency in growth medium, changing the medium
every other day. Once confluent (Day -1), cells were maintained in WA Growth
medium for 24 h. On day 0 differentiation of pre-adipocytes was induced for 48 h
(Day 0–Day +2) by changing the medium to WA Induction medium (DMEM
containing 5% FBS, 1% P/S, 1 nM T3, 0.172 µM insulin, 50mg/ml L-ascorbate, 1 mM
D-biotin, 17mM panthothenate, 1 µM Rosiglitazone, 0.25 µM dexamethasone and
0.5mM 3-isobutyl-1-methylxantine). From day +2 until day +12, cells were
maintained in WAMaintenance medium (DMEM containing 5% FBS, 1% P/S, 1 nM
T3, 0.172 µM insulin, 50mg/ml L-ascorbate, 1 mM D-biotin, 17mM panthothenate),
refreshing it every other day. Starting on Day 0, cells were chronically treated with
1 µM NE, 1 µM BAY-60 or their combination. Medium and treatment were
refreshed every other day. All cells were analyzed on Day +12, with the exception of
PINK1 analysis that was performed on 80% confluent cells.
Immunoprecipitation and Western blotting. Cells were washed twice with PBS
and lysed for 5 min with RIPA buffer containing cOmpleteTM EDTA-free protease
inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail (Roche).
Pellets were clarified by centrifugation at 10,000 rpm for 10 min at 4 °C and the
supernatant and incubated at 4 °C for 2 h with 25 µL of anti-RFP/GFP/Myc
antibody-linked beads (Chromotek) or anti-FLAG M2 beads (Sigma), respectively,
or untagged beads (Chromotek), as a control. (For immunoprecipitation of
endogenous proteins, the supernatant was pre-cleared by incubation with Protein-
G agarose beads (Invitrogen). The supernatant was then incubated for 2 h with the
appropriate antibody at 4 °C and overnight incubation with Protein-G agarose
beads, as previously described72. Beads were pelleted by centrifugation for 1 min at
5000 × g, washed 3–5× with wash buffer (Tris-HCl 0.1 M, NaCl 0.3 M, Triton X-
100 1% (v/v), pH 7.5) followed by elution with 1× sample buffer and spin-down.
Whenever appropriate, a 5 min incubation at 90 °C was performed during elution.
The immunoprecipitate was loaded and separated on SDS-PAGE gels and subse-
quently transferred to PVDF membranes (Millipore). After transfer, PVDF
membranes were blocked for 1 h at room temperature in 5% skimmed milk
(Sigma) TBS-T (Alfa Aesar)and incubated overnight at 4 °C with primary antibody
diluted in 5% skimmed milk/TBS-T. After three washes with TBS-T membranes
were incubated at room temperature for 1 h with a peroxidase-conjugated sec-
ondary antibody. After three washes with TBS-T, chemiluminescent detection was
performed with a Compact X4 Automatic Processor (Xograph) and the signal was
developed using ECL Western Blotting Substrate (Thermo Scientific). Quantifica-
tion of band intensity was accomplished by densitometry using ImageJ software
(http://rsbweb.nih.gov/ij/index.html). The extent of protein phosphorylation was
calculated as the ratio between the density of the band corresponding to the
phosphorylated protein and the density of the band corresponding to total protein.
Values were normalised using GraphPad Prism software (GraphPad Software, Inc.,
CA, USA),
White adipocytes were homogenized in RIPA buffer containing the above
mentioned protease and phosphatase inhibitors. After centrifugation (10,000 × g,
30 min, 4 °C), the supernatants were collected, and protein concentration was
determined with Bradford reagent. Western blot analysis was performed as
described by the manufacturer with rabbit anti-uncoupling protein 1 (UCP-1,
Thermo Fisher Scientific) and rabbit anti-calnexin antibodies (Anti-Calnexin, C-
Terminal, EMD Milipore Corp, USA). The bands were visualized with an Odyssey
imaging system (LI-COR Bioscience, Lincoln, NE, USA) with fluorescence-labeled
secondary antibodies (Anti-rabbit IgG (H+ L) – Dylight 800, 4× PEG Conjugate,
Cell Signaling Technology), according to the manufacturer’s protocol. UCP1 and
PINK1 signals were normalized to Calnexin.
Uncropped images of all full blots are shown in the Supplementary Material.
Live cell confocal imaging. Fluorescence imaging was performed 24 h after cell
transfection. Cells were kept at RT in Dulbecco’s PBS (DPBS; Life Technologies)
Fig. 8 Effect of PDE2A2 inhibition on adipocyte browning. a Representative western blot and b quantification of PINK1 in primary white adipocytes treated
with forskolin or BAY-60 in the presence of the mitochondrial uncoupler CCCP with or without stimulation of the beta-adrenergic receptor with
Isoprenaline (ISO). The amount of PINK1 is normalized to Calnexin and is shown as fold change relative to levels in CCCP-treated cells. Data are mean ±
s.e.m, N= 5. c mRNA expression of nuclear-encoded mitochondrial and thermogenic genes in primary white adipocytes treated with 1 μM NE, 1 μM BAY-
60 or 1 μM NE+ 1 μM BAY-60. mRNA level is shown as the fold change relative to levels in non-treated cells, N= 7. d Representative western blot and
e quantification of UCP1 from primary white adipocytes treated with 1 μM NE, 1 μM BAY-60 or 1 μM NE+ 1 μM BAY-60. The amount of UCP1 is shown as
the fold change relative to levels in non-treated cells. N= 4. f mRNA expression of mitochondria-encoded genes in primary white adipocytes treated with
1 μM NE, 1 μM BAY-60 or 1 μM NE+ 1 μM BAY-60. mRNA level is shown as the fold change relative to levels of Hprt N= 5. g UCP1-dependent oxygen
consumption of primary white adipocytes treated with with 1 μM NE, 1 μM BAY-60 or 1 μM NE+ 1 μM BAY-60, N= 6. h Representative images (left) and
quantification (right) of the average lipid droplet size of primary white adipocytes treated with with 1 µM NE, 1 µM BAY-60 or 1 µM NE+ 1 µM BAY-60,
N= 5. All values are expressed as mean ± s.e.m. One-way ANOVA and Tukey’s multiple comparison tests were performed for (c, e–h). Student’s t-test
statistical analysis was performed for (b). *P < 0.05; **P < 0.01; ***P < 0.005; ns= not significant.
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and imaged on a Fluoview FV1000 microscope, which is an inverted IX81 confocal
system (Olympus, Tokyo, Japan), using a 60X, NA 1.35 oil immersion UPlanSApo
objective (Olympus). The microscope was equipped with a Becker and Hickl FLIM
system and with fluorescence filters suitable for UV and green or red dyes. Images
were acquired using FluoView viewer software (FV10-ASW software, Olympus)
and processed using ImageJ.
Parkin recruitment. mCherry-Parkin-expressing MEFs were treated with the
indicated reagents, followed by CCCP incubation (10 μM, 3 h) except where
indicated. Intracellular localization of mCherry-Parkin was analyzed under fluor-
escence microscopy using MetaFluor software.
The extent of overlap between LC3-GFP and mRFP (mitochondrial marker)
was quantified using Mander’s coefficient (ImageJ, Coloc 2 plugin). LC3 puncta
analysis was performed by auto-thresholding images (ImageJ) and quantifying the
number of puncta.
Immunofluorescence. Cells were fixed with 8% paraformaldehyde in TBS (Tris-
buffered saline) for 10 min, washed in TBS, permeabilized with 0.5% (v/v) Triton
X-100 (TX) in TBS for 5 min and washed in TBS. Non-specific labeling was
blocked with a 10 min incubation of 1% normal goat serum (NGS; v/v) in Antibody
Diluting Solution (AbDil; TBS 0.1% TX, 2% BSA and 0.1% Sodiumazide) and
all antibodies were diluted in AbDil 1% NGS. Primary antibodies were incubated
for 60 min. After 3 × 5 min washes cells were treated with fluorescent-conjugated
species-specific immunoglobulins (1:250 in AbDil 1% NGS) for 60 min. After
3 ×5 min TBS washes, coverslips were mounted in Ibidi mounting media and
sealed with nail varnish.
FRET imaging. Cells expressing OMM-H9031 were imaged on an inverted
microscope (Olympus IX71) using a PlanApoN, 60X, NA 1.42 oil immersion
objective, 0.17/FN 26.5 (Olympus, UK). The microscope was equipped with a
CoolSNAP HQ2 cooled CCD camera (Photometrics) and a DV2 beam-splitter
(MAG Biosystems, Photometrics) for simultaneous imaging of CFP and YFP
emissions. The FRET filters used were: CFP excitation filter ET436/20×, dichroic
mirror 455DCLP (all from Chroma Technology) in the microscope filter cube;
dichroic mirror 505dcxr, YFP emission filter 535/30 m, CFP emission filter 480/
30 m (Chroma Technology) in the beam splitter. Images were acquired using
Metafluor software. Changes in cAMP concentration were monitored by measuring
CFP (480 nm)/YFP (535 nm) fluorescence emission values upon excitation of the
transfected cells at 430 nm. FRET changes are expressed as relative to maximal
FRET change at saturation (25 μM forskolin+ 100 μM IBMX).
Mito-QC imaging. MEFWT expressing mito-QC43 were a generous gift from Dr
Ian Ganley (University of Dundee, UK). Cells were seeded on 24 mm diameter
coverslips, grown for 24 h in 6-well plates in DMEM, supplemented with 10% FBS
(Gibco, Art. No. 10270), 100 units/mL penicillin, 100 µg/mL streptomycin, and
2 mM glutamine at 37 °C, 5% CO2 and then subjected to the relevant treatments.
Cells were washed three times, fixed with 4% Paraformaldehyd (15 min), washed
again 3 times and then stored at 4 °C until imaged. Widefield image acquisition was
performed with MetaFluor (Universal Imaging) on an Olympus IX 71 inverted
microscope at 60x magnification (Plan Apochromat N 60X NA 1.42 oil immersion)
equipped with a Photometrics HQ2 camera. Excitation/emission wavelength was
500 ± 10 and 535 ± 15 for GFP and 562 ± 20 and 624 ± 20 for RFP. For immuno-
fluorescence of cells expressing mito-QC and Flag-PDEs, cells were incubated with
Anti-FLAG antibody (DYKDDDDK-Tag, Anti-Rabbit, Cell Signaling, Cat. No.
2368S, 02-2017, lot 12) 1:1000 in 1% BSA overnight at 4 °C or for 2 h at RT. Cells
were then washed 3 times and incubated for 2 h (RT) with 1:400 secondary anti-
body (AlexaFluor 633, Goat-Anti-Rabbit, Cat.No. A21070, Invitrogen) in 1% BSA.
Finally cells were washed again three times and stored light protected at 4 °C until
imaged. All dilutions were in PBS containing 20 mM HEPES/pH 7.0. For quanti-
tation, red-alone puncta were counted in at least ten fields of view from at least
three independent experiments for each condition. A threshold of 3 or more red-
alone puncta per cell was applied to the data to determine the number of cells
undergoing mitophagy. Data were expressed as percent of cells with mitophagy or
as average number of red-alone puncta per cell.
Molecular biology. Isolation of RNA from cells was performed by using innu-
SOLV RNA Reagent. Final concentration of RNA was quantified using a Nanodrop
Spectrophotometer. Following the manufacturer’s instructions, 1000 ng of RNA
were transcribed using the “Transcriptor First Strand cDNA Synthesis Kit”
(Roche). mRNA of the target genes was amplified and quantified by using the
transcribed cDNA. mRNA expression was assessed by qRT-PCR using a HT7900
instrument from Applied Biosystems and SYBR-Green PCR master mix (Applied
Biosystems). Quantification of mRNA levels was performed based on the crossing
point values of the amplification curves using the second derivative maximum
method. Hprt (Hypoxanthine-guaninephosphoribosyltransferase) was used as an
internal control.
The primer sequences used to amplify the target genes are shown in
Supplementary Table 1
UCP1-dependent respiration. Primary white adipocytes were treated as described
above (1 μM BAY, 1 μM NE). On day 12 the measurements were conducted using
an Oxygraph 2 K (Oroboros Instruments). Samples were transferred to the oxy-
graph chamber containing 2 ml incubation medium (0.5 mM EGTA, 3 mM MgCl2
6H2O, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES,
110 mM sucrose and 1 g/l BSA, pH 7.1). In vitro respiration levels were recorded
when reaching a steady state followed by addition of substrates (State 1: endo-
genous; state 2: Pyruvate-Malate-Glutamate [PMG]; state 3: Succinate; state 4:
GDP;). Respiration rates were normalised to total protein content and UCP1
respiration was calculated from the difference between GDP and PMG
respiration rates.
Determination of lipid droplet size. Primary white adipocytes were treated as
indicated above. On day 12, images were acquired through automated digital
microscopy by CytationTM 5 (BioTek). Three images per well were automatically
taken. Image processing and calculation of the average lipid droplet size was done
using the Gen5TM software provided (min. object size: 1 µM; max. object size:
40 µM).
Statistics and reproducibility. Data are presented as means ± standard error of
the mean. The significance of differences between multiple groups were compared
by one-way or two-way analysis of variance (ANOVA), as appropriate, followed by
a Tukey’s or Sidak’s multiple comparisons tests. Two-group analysis was per-
formed by two-tailed Student’s t-test. Number of replicates is indicated in the figure
legends: N indicates number of biological replicates; n indicates number of
observations. Differences were considered significant at p < 0.05, with *p < 0.05;
**p < 0.01; ***p < 0.005; ns= not significant. All data were analysed using
GraphPad Prism 5.01 or Prism 8.43 software
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated or analysed during this study are included in this published article
(and its supplementary information files). Source data behind the graphs can be found in
Supplementary Data 3. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE73 partner repository with the dataset
identifier PXD020486.
Received: 28 August 2019; Accepted: 17 September 2020;
References
1. Vilardaga, J. P., Jean-Alphonse, F. G. & Gardella, T. J. Endosomal generation
of cAMP in GPCR signaling. Nat. Chem. Biol. 10, 700–706 (2014).
2. Zippin, J. H. et al. Compartmentalization of bicarbonate-sensitive adenylyl
cyclase in distinct signaling microdomains. FASEB J. 17, 82–84 (2003).
3. Musheshe, N., Schmidt, M. & Zaccolo, M. cAMP: from long-range second
messenger to nanodomain signalling. Trends Pharmacol. Sci. 39, 209–222
(2018).
4. Wong, W. & Scott, J. D. AKAP signalling complexes: focal points in space and
time. Nat. Rev. Mol. Cell Biol. 5, 959–970 (2004).
5. Gorshkov, K. et al. AKAP-mediated feedback control of cAMP gradients in
developing hippocampal neurons. Nat. Chem. Biol. 13, 425–431 (2017).
6. Surdo, N. C. et al. FRET biosensor uncovers cAMP nano-domains at beta-
adrenergic targets that dictate precise tuning of cardiac contractility. Nat.
Commun. 8, 15031 (2017).
7. Zaccolo, M. & Pozzan, T. Discrete microdomains with high concentration of
cAMP in stimulated rat neonatal cardiac myocytes. Science 295, 1711–1715
(2002).
8. Maurice, D. H. et al. Advances in targeting cyclic nucleotide
phosphodiesterases. Nat. Rev. Drug Discov. 13, 290–314 (2014).
9. Houslay, M. D. Underpinning compartmentalised cAMP signalling through
targeted cAMP breakdown. Trends Biochem. Sci. 35, 91–100 (2010).
10. Nunnari, J. & Suomalainen, A. Mitochondria: in sickness and in health. Cell
148, 1145–1159 (2012).
11. Chan, D. C. Dissecting mitochondrial fusion. Dev. Cell 11, 592–594 (2006).
12. Palikaras, K., Lionaki, E. & Tavernarakis, N. Mechanisms of mitophagy in
cellular homeostasis, physiology and pathology. Nat. Cell Biol. 20, 1013–1022
(2018).
13. Carlucci, A., Lignitto, L. & Feliciello, A. Control of mitochondria dynamics
and oxidative metabolism by cAMP, AKAPs and the proteasome. Trends Cell
Biol. 18, 604–613 (2008).
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01311-7
14 COMMUNICATIONS BIOLOGY |           (2020) 3:596 | https://doi.org/10.1038/s42003-020-01311-7 | www.nature.com/commsbio
14. Lefkimmiatis, K. & Zaccolo, M. cAMP signaling in subcellular compartments.
Pharmacol. Ther. 143, 295–304 (2014).
15. Valsecchi, F., Ramos-Espiritu, L. S., Buck, J., Levin, L. R. & Manfredi, G.
cAMP and mitochondria. Physiology 28, 199–209 (2013).
16. Rinaldi, L., Delle Donne, R., Borzacchiello, D., Insabato, L. & Feliciello, A. The
role of compartmentalized signaling pathways in the control of mitochondrial
activities in cancer cells. Biochim Biophys. Acta Rev. Cancer 1869, 293–302
(2018).
17. Cribbs, J. T. & Strack, S. Reversible phosphorylation of Drp1 by cyclic AMP-
dependent protein kinase and calcineurin regulates mitochondrial fission and
cell death. EMBO Rep. 8, 939–944 (2007).
18. Cereghetti, G. M. et al. Dephosphorylation by calcineurin regulates
translocation of Drp1 to mitochondria. Proc. Natl Acad. Sci. USA 105,
15803–15808 (2008).
19. Akabane, S. et al. PKA regulates PINK1 stability and Parkin recruitment to
damaged mitochondria through phosphorylation of MIC60. Mol. Cell 62,
371–384 (2016).
20. Pfeifer, A. & Hoffmann, L. S. Brown, beige, and white: the new color code of
fat and its pharmacological implications. Annu. Rev. Pharmacol. Toxicol. 55,
207–227 (2015).
21. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological
significance. Physiol. Rev. 84, 277–359 (2004).
22. Ikeda, K., Maretich, P. & Kajimura, S. The common and distinct features of
brown and beige adipocytes. Trends Endocrinol. Metab. 29, 191–200 (2018).
23. Cinti, S. Between brown and white: novel aspects of adipocyte differentiation.
Ann. Med. 43, 104–115 (2011).
24. Chen, Q., Lin, R. Y. & Rubin, C. S. Organelle-specific targeting of protein
kinase AII (PKAII). Molecular and in situ characterization of murine A kinase
anchor proteins that recruit regulatory subunits of PKAII to the cytoplasmic
surface of mitochondria. J. Biol. Chem. 272, 15247–15257 (1997).
25. Means, C. K. et al. An entirely specific type I A-kinase anchoring protein that
can sequester two molecules of protein kinase A at mitochondria. Proc. Natl
Acad. Sci. USA 108, E1227–E1235 (2011).
26. Monterisi, S. & Zaccolo, M. Components of the mitochondrial cAMP
signalosome. Biochem. Soc. Trans. 45, 269–274 (2017).
27. Stroop, S. D. & Beavo, J. A. Structure and function studies of the cGMP-
stimulated phosphodiesterase. J. Biol. Chem. 266, 23802–23809 (1991).
28. Wu, A. Y., Tang, X. B., Martinez, S. E., Ikeda, K. & Beavo, J. A. Molecular
determinants for cyclic nucleotide binding to the regulatory domains of
phosphodiesterase 2A. J. Biol. Chem. 279, 37928–37938 (2004).
29. Stephenson, D. T. et al. Immunohistochemical localization of
phosphodiesterase 2A in multiple mammalian species. J. Histochem.
Cytochem. 57, 933–949 (2009).
30. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new
target for the development of specific therapeutic agents. Pharmacol. Ther.
109, 366–398 (2006).
31. Monterisi, S. et al. PDE2A2 regulates mitochondria morphology and apoptotic
cell death via local modulation of cAMP/PKA signalling. Elife 6, e21374
(2017).
32. Acin-Perez, R. et al. A phosphodiesterase 2A isoform localized to
mitochondria regulates respiration. J. Biol. Chem. 286, 30423–30432 (2011).
33. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed
normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol.
Cell. Proteom. 13, 2513–2526 (2014).
34. Cercek, B. & Houslay, M. D. Submitochondrial localization and asymmetric
disposition of two peripheral cyclic nucleotide phosphodiesterases. Biochem. J.
207, 123–132 (1982).
35. Bohnert, M. et al. Role of mitochondrial inner membrane organizing system in
protein biogenesis of the mitochondrial outer membrane. Mol. Biol. Cell 23,
3948–3956 (2012).
36. Xie, J., Marusich, M. F., Souda, P., Whitelegge, J. & Capaldi, R. A. The
mitochondrial inner membrane protein mitofilin exists as a complex with
SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-
containing protein 3 and 6 and DnaJC11. FEBS Lett. 581, 3545–3549 (2007).
37. Harner, M. et al. The mitochondrial contact site complex, a determinant of
mitochondrial architecture. EMBO J. 30, 4356–4370 (2011).
38. Korner, C. et al. The C-terminal domain of Fcj1 is required for formation of
crista junctions and interacts with the TOB/SAM complex in mitochondria.
Mol. Biol. Cell 23, 2143–2155 (2012).
39. Ozawa, T. et al. A minimal peptide sequence that targets fluorescent and
functional proteins into the mitochondrial intermembrane space. ACS Chem.
Biol. 2, 176–186 (2007).
40. Lu, X. et al. Mitophagy controls beige adipocyte maintenance through a
Parkin-dependent and UCP1-independent mechanism. Sci. Signal 11,
eaap8526 (2018).
41. Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited
selectively to impaired mitochondria and promotes their autophagy. J. Cell
Biol. 183, 795–803 (2008).
42. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for
monitoring autophagy (3rd edition). Autophagy 12, 1–222 (2016).
43. Allen, G. F., Toth, R., James, J. & Ganley, I. G. Loss of iron triggers PINK1/
Parkin-independent mitophagy. EMBO Rep. 14, 1127–1135 (2013).
44. Zoccarato, A. et al. Cardiac hypertrophy is inhibited by a local pool of cAMP
regulated by phosphodiesterase 2. Circ. Res. 117, 707–719 (2015).
45. Matsuda, N. et al. PINK1 stabilized by mitochondrial depolarization recruits
Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J.
Cell Biol. 189, 211–221 (2010).
46. Okatsu, K. et al. PINK1 autophosphorylation upon membrane potential
dissipation is essential for Parkin recruitment to damaged mitochondria. Nat.
Commun. 3, 1016 (2012).
47. Stangherlin, A. et al. cGMP signals modulate cAMP levels in a compartment-
specific manner to regulate catecholamine-dependent signaling in cardiac
myocytes. Circ. Res. 108, 929–939 (2011).
48. Ding, W. X. & Yin, X. M. Mitophagy: mechanisms, pathophysiological roles,
and analysis. Biol. Chem. 393, 547–564 (2012).
49. Conti, M. & Beavo, J. Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling.
Annu. Rev. Biochem. 76, 481–511 (2007).
50. Angelova, P. R. & Abramov, A. Y. Functional role of mitochondrial reactive
oxygen species in physiology. Free Radic. Biol. Med. 100, 81–85 (2016).
51. Di Benedetto, G., Scalzotto, E., Mongillo, M. & Pozzan, T. Mitochondrial Ca
(2)(+) uptake induces cyclic AMP generation in the matrix and modulates
organelle ATP levels. Cell Metab. 17, 965–975 (2013).
52. Ugarte-Uribe, B. & Garcia-Saez, A. J. Apoptotic foci at mitochondria: in and
around Bax pores. Philos. Trans. R. Soc. Lond. B Biol. Sci. 372, 20160217
(2017).
53. John, G. B. et al. The mitochondrial inner membrane protein mitofilin
controls cristae morphology. Mol. Biol. Cell 16, 1543–1554 (2005).
54. Wollweber, F., von der Malsburg, K. & van der Laan, M. Mitochondrial contact
site and cristae organizing system: a central player in membrane shaping and
crosstalk. Biochim Biophys. Acta Mol. Cell Res. 1864, 1481–1489 (2017).
55. Tsai, P. I. et al. PINK1 phosphorylates MIC60/mitofilin to control structural
plasticity of mitochondrial crista junctions. Mol. Cell 69, 744–756 e746 (2018).
56. Narendra, D. P. et al. PINK1 is selectively stabilized on impaired mitochondria
to activate Parkin. PLoS Biol. 8, e1000298 (2010).
57. McWilliams, T. G. & Muqit, M. M. PINK1 and Parkin: emerging themes in
mitochondrial homeostasis. Curr. Opin. Cell Biol. 45, 83–91 (2017).
58. McWilliams, T. G. et al. Basal mitophagy occurs independently of PINK1 in
mouse tissues of high metabolic demand. Cell Metab. 27, 439–449 e435
(2018).
59. McWilliams, T. G. et al. Mito-QC illuminates mitophagy and mitochondrial
architecture in vivo. J. Cell Biol. 214, 333–345 (2016).
60. Lee, J. J. et al. Basal mitophagy is widespread in Drosophila but minimally
affected by loss of Pink1 or parkin. J. Cell Biol. 217, 1613–1622 (2018).
61. Kovanich, D. et al. Sphingosine kinase interacting protein is an A-kinase
anchoring protein specific for type I cAMP-dependent protein kinase.
Chembiochem 11, 963–971 (2010).
62. Ruiz-Stewart, I. et al. Guanylyl cyclase is an ATP sensor coupling nitric oxide
signaling to cell metabolism. Proc. Natl Acad. Sci. USA 101, 37–42 (2004).
63. Feil, R. & Kemp-Harper, B. cGMP signalling: from bench to bedside.
Conference on cGMP generators, effectors and therapeutic implications.
EMBO Rep. 7, 149–153 (2006).
64. Reverte-Salisa, L., Sanyal, A. & Pfeifer, A. Role of cAMP and cGMP signaling
in brown fat. Handb. Exp. Pharmacol. 251, 161–182 (2019).
65. Altshuler-Keylin, S. et al. Beige adipocyte maintenance is regulated by
autophagy-induced mitochondrial clearance. Cell Metab. 24, 402–419 (2016).
66. Choo, H. J. et al. Mitochondria are impaired in the adipocytes of type 2
diabetic mice. Diabetologia 49, 784–791 (2006).
67. Asterholm, I. W., Mundy, D. I., Weng, J., Anderson, R. G. & Scherer, P. E.
Altered mitochondrial function and metabolic inflexibility associated with loss
of caveolin-1. Cell Metab. 15, 171–185 (2012).
68. Hernandez-Fernaud, J. R. et al. Secreted CLIC3 drives cancer progression
through its glutathione-dependent oxidoreductase activity. Nat. Commun. 8,
14206 (2017).
69. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,
individualized p.p.b.-range mass accuracies and proteome-wide protein
quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
70. Tyanova, S. et al. The Perseus computational platform for comprehensive
analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
71. Mitschke, M. M. et al. Increased cGMP promotes healthy expansion and
browning of white adipose tissue. FASEB J. 27, 1621–1630 (2013).
72. Lobo, M. J., Amaral, M. D., Zaccolo, M. & Farinha, C. M. EPAC1 activation by
cAMP stabilizes CFTR at the membrane by promoting its interaction with
NHERF1. J. Cell Sci. 129, 2599–2612 (2016).
73. Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in
2019: improving support for quantification data. Nucleic Acids Res. 47,
D442–D450 (2019).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01311-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:596 | https://doi.org/10.1038/s42003-020-01311-7 | www.nature.com/commsbio 15
Acknowledgements
The authors would like to thank Dr Ian Ganley for providing the mito-QC MEFs and
Prof Miles Housley for critically reviewing an early version of the manuscript. This study
was supported by the British Heart Foundation (PG/10/75/28537, PG/15/5/31110, RG/
17/6/32944 and RG/12/3/29423), the BHF Centre of Research Excellence, Oxford (RE/
08/004 and RE/13/1/30181) to M.Z., Medical Research Council (MR/K501256/1) and St.
John’s College to M.J.L. and Cancer Research UK grant A12935 to S.Z.
Author contributions
M.J.L., L.R-S., F.G., A.F., A.K., Y-C.C., G.S., S.Z., and M.Z. designed experiments and
analysed data. M.J.L., L.R-S., F.G., A.K., Y-C.C., G.S., S.P., N.L., and E.P. performed
experiments and analysed data. M.Z. and M.J.L. wrote the manuscript. M.Z. conceived
research question and oversaw the entirety of research.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s42003-
020-01311-7.
Correspondence and requests for materials should be addressed to M.Z.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01311-7
16 COMMUNICATIONS BIOLOGY |           (2020) 3:596 | https://doi.org/10.1038/s42003-020-01311-7 | www.nature.com/commsbio
